ConvaTec Group Plc (CNVVY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ConvaTec Group Plc (CNVVY) with AI Score 43/100 (Weak). ConvaTec Group Plc is a global medical technology company focused on developing and marketing products for wound care, ostomy care, continence and critical care, and infusion devices. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026ConvaTec Group Plc (CNVVY) Healthcare & Pipeline Overview
ConvaTec Group Plc, a global medical technology company, specializes in advanced wound care, ostomy care, continence and critical care, and infusion devices, serving healthcare providers and patients worldwide. With a focus on innovation and a diverse product portfolio, ConvaTec addresses critical needs in chronic care management and acute healthcare settings.
Investment Thesis
ConvaTec Group Plc presents a notable research candidate within the medical technology sector. With a market capitalization of $6.10 billion and a P/E ratio of 35.10, the company demonstrates a solid financial foundation. A key value driver is the company's strong presence in the advanced wound care and ostomy care markets, which are expected to grow due to the aging global population and increasing prevalence of chronic diseases. The company's dividend yield of 2.12% offers an attractive income stream for investors. However, potential risks include increasing competition in the medical device industry and regulatory changes that could impact product approvals and market access.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $6.10 billion, reflecting a substantial presence in the medical technology sector.
- P/E ratio of 35.10, indicating investor confidence in the company's earnings potential.
- Profit margin of 7.2%, showcasing the company's ability to generate profits from its revenue.
- Gross margin of 55.8%, demonstrating efficient cost management in product manufacturing and distribution.
- Dividend yield of 2.12%, providing a steady income stream for investors.
Competitors & Peers
Strengths
- Strong market position in wound care and ostomy care.
- Diverse product portfolio addressing multiple healthcare needs.
- Established distribution network and relationships with healthcare providers.
- Global presence with sales in multiple regions.
Weaknesses
- Dependence on specific product categories.
- Exposure to regulatory changes and pricing pressures.
- Limited presence in emerging markets compared to some competitors.
- Potential for product recalls or safety concerns.
Catalysts
- Upcoming: Potential regulatory approvals for new wound care products in key markets by Q4 2026.
- Ongoing: Increasing adoption of ConvaTec's ostomy care products in emerging markets, driven by rising awareness and access to healthcare.
- Ongoing: Strategic partnerships with healthcare providers to expand the reach of ConvaTec's continence and critical care solutions.
- Upcoming: Launch of new digital health solutions for remote wound care management in H2 2026.
Risks
- Potential: Increasing competition from other medical device companies in the wound care and ostomy care markets.
- Potential: Changes in healthcare regulations and reimbursement policies affecting the pricing and adoption of ConvaTec's products.
- Ongoing: Currency fluctuations impacting the value of ConvaTec's international sales and earnings.
- Potential: Product liability claims or recalls affecting the company's reputation and financial performance.
Growth Opportunities
- Expansion in Emerging Markets: ConvaTec can capitalize on the growing healthcare expenditure in emerging markets, particularly in Asia and Latin America. These regions present significant opportunities for growth in wound care and ostomy care products, driven by increasing awareness and access to healthcare services. Targeted marketing strategies and partnerships with local distributors can facilitate market penetration. This expansion could contribute to a 10-15% increase in revenue over the next 3-5 years.
- Product Innovation and R&D: Investing in research and development to create innovative medical technologies and products can drive future growth. Focusing on advanced wound care solutions and smart medical devices can differentiate ConvaTec from competitors. Successful product launches in these areas could lead to a 5-7% increase in annual revenue growth. The timeline for realizing these benefits is approximately 2-4 years, contingent on successful clinical trials and regulatory approvals.
- Strategic Acquisitions: Pursuing strategic acquisitions of smaller medical device companies with complementary technologies or market access can accelerate growth. Acquiring companies specializing in niche areas like advanced wound closure or specialized ostomy solutions can broaden ConvaTec's product portfolio and expand its customer base. This strategy could contribute to a 8-12% increase in market share within 3 years.
- Digital Health Integration: Integrating digital health technologies into its product offerings, such as remote monitoring and telehealth solutions for wound care management, can enhance patient outcomes and improve efficiency. Developing partnerships with telehealth providers and creating user-friendly mobile applications can drive adoption. The potential market for digital health solutions in wound care is estimated to reach $5 billion by 2028.
- Partnerships with Healthcare Providers: Strengthening partnerships with hospitals, clinics, and other healthcare providers can ensure wider adoption of ConvaTec's products. Offering training programs, educational resources, and customized solutions can enhance the value proposition for healthcare professionals. These collaborations can lead to increased sales and brand loyalty, contributing to a 3-5% increase in annual revenue.
Opportunities
- Expansion in emerging markets with growing healthcare expenditure.
- Development of innovative medical technologies and products.
- Strategic acquisitions of smaller companies with complementary technologies.
- Integration of digital health technologies into product offerings.
Threats
- Increasing competition from other medical device companies.
- Changes in healthcare regulations and reimbursement policies.
- Economic downturns affecting healthcare spending.
- Potential for product liability claims.
Competitive Advantages
- Strong brand reputation in specialized medical product categories.
- Established distribution network and relationships with healthcare providers.
- Proprietary technologies and patents in wound care and ostomy care.
- Diverse product portfolio addressing multiple healthcare needs.
About CNVVY
Founded in 1978 and headquartered in Reading, United Kingdom, ConvaTec Group Plc has evolved into a leading global medical technology company. The company develops, manufactures, and markets a wide range of innovative medical products and technologies, focusing on four core areas: advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's advanced wound care products include dressings and skin care solutions for chronic and acute wounds, addressing conditions like diabetes, immobility, and venous disease. Their ostomy care products provide devices, accessories, and services for individuals with a stoma, resulting from conditions such as colorectal cancer and inflammatory bowel disease. The company's continence and critical care offerings include urinary catheters and products for urinary continence, as well as devices used in intensive care units. Additionally, ConvaTec provides disposable infusion sets for insulin pumps used in diabetes management and other continuous infusion treatments. ConvaTec serves a diverse customer base, including healthcare providers, patients, and manufacturers, selling its products directly or through distributors and wholesalers to pharmacies, hospitals, and other healthcare service providers.
What They Do
- Develops and manufactures advanced wound dressings and skin care products.
- Provides devices and accessories for ostomy care.
- Offers continence and critical care products, including urinary catheters.
- Supplies disposable infusion sets for insulin pumps.
- Markets products to pharmacies, hospitals, and healthcare providers.
- Serves healthcare providers, patients, and manufacturers globally.
Business Model
- Develops and manufactures medical products and technologies.
- Sells products directly or through distributors and wholesalers.
- Generates revenue from sales of wound care, ostomy care, continence and critical care, and infusion devices.
- Focuses on innovation and product development to maintain a competitive edge.
Industry Context
ConvaTec Group Plc operates in the global medical instruments and supplies industry, which is characterized by continuous innovation and increasing demand driven by an aging population and the rising prevalence of chronic diseases. The industry is highly competitive, with key players focusing on developing advanced technologies and expanding their product portfolios. ConvaTec competes with companies like DSRLF, FLMNF, FLMNY, GNGBY, and RADLY, all vying for market share in specialized segments like wound care and ostomy care. The industry is also subject to stringent regulatory requirements and pricing pressures.
Key Customers
- Healthcare providers, including hospitals and clinics.
- Patients requiring wound care, ostomy care, and continence care.
- Manufacturers of insulin pumps and other medical devices.
- Pharmacies and other retail outlets.
Financials
Chart & Info
ConvaTec Group Plc (CNVVY) stock price: Price data unavailable
Latest News
-
Convatec Introduces Co-Branded eakin freeseal® Ostomy Seal in North America, Expanding the ESENTA™ Family of Accessories
businesswire.com · Mar 16, 2026
-
Convatec Group PLC (CNVVY) Q4 2025 Earnings Call Transcript
seekingalpha.com · Feb 24, 2026
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Highs On Friday
· Jan 10, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CNVVY.
Price Targets
Wall Street price target analysis for CNVVY.
MoonshotScore
What does this score mean?
The MoonshotScore rates CNVVY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Convatec Introduces Co-Branded eakin freeseal® Ostomy Seal in North America, Expanding the ESENTA™ Family of Accessories
Convatec Group PLC (CNVVY) Q4 2025 Earnings Call Transcript
Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Friday
Leadership: Jonathan Peter Mason
Chief Executive Officer
Jonathan Peter Mason serves as the Chief Executive Officer of ConvaTec Group Plc. His career spans various leadership roles in the healthcare and consumer goods industries. Before joining ConvaTec, he held senior positions at prominent multinational corporations, where he focused on driving growth, improving operational efficiency, and enhancing customer satisfaction. His educational background includes advanced degrees in business administration and engineering, providing him with a strong foundation in both strategic management and technical expertise.
Track Record: Under Jonathan Peter Mason's leadership, ConvaTec Group Plc has focused on expanding its product portfolio, strengthening its market position in key segments, and improving its financial performance. Key achievements include successful product launches, strategic acquisitions, and initiatives to enhance operational efficiency. He has also emphasized innovation and digital transformation to drive long-term growth.
ConvaTec Group Plc ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. CNVVY functions as a Level 1 ADR, meaning it trades over-the-counter (OTC) without needing to meet the strict listing requirements of exchanges like the NYSE or NASDAQ. This allows U.S. investors to invest in ConvaTec Group Plc more easily.
- Home Market Ticker: London Stock Exchange (LSE), United Kingdom
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: CNVV
CNVVY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ConvaTec Group Plc has limited regulatory oversight and disclosure requirements compared to companies listed on major exchanges like the NYSE or NASDAQ. Companies in this tier may not be required to file regular financial reports with the SEC, leading to less transparency and potentially higher investment risk.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and disclosure requirements.
- Potential for lower trading volume and wider bid-ask spreads.
- Increased risk of fraud or manipulation.
- Greater price volatility compared to stocks listed on major exchanges.
- Uncertainty regarding the availability of financial information.
- Verify the company's registration and legal status.
- Review available financial reports and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price movements.
- Consult with a financial advisor before investing.
- Established business operations and product offerings.
- Presence of a recognized management team.
- Availability of some financial information, even if limited.
- Positive news coverage or industry recognition.
- Active investor relations or communication efforts.
CNVVY Healthcare Stock FAQ
What does ConvaTec Group Plc do?
ConvaTec Group Plc is a global medical technology company focused on developing, manufacturing, and marketing innovative products and technologies in four core areas: advanced wound care, ostomy care, continence and critical care, and infusion devices. The company's products are used by healthcare providers, patients, and manufacturers worldwide, addressing critical needs in chronic care management and acute healthcare settings. ConvaTec sells its products directly or through distributors and wholesalers to pharmacies, hospitals, and other healthcare service providers.
What do analysts say about CNVVY stock?
Analyst consensus on CNVVY stock is currently mixed, with some analysts expressing optimism about the company's growth prospects in the wound care and ostomy care markets, while others are more cautious due to increasing competition and regulatory uncertainties. Key valuation metrics, such as the P/E ratio and dividend yield, are closely monitored by analysts to assess the stock's attractiveness. Growth considerations include the company's ability to expand in emerging markets and develop innovative products.
What are the main risks for CNVVY?
The main risks for CNVVY include increasing competition in the medical device industry, which could put pressure on pricing and market share. Regulatory changes and reimbursement policies could also impact the company's financial performance. Currency fluctuations pose a risk to ConvaTec's international sales and earnings. Additionally, product liability claims or recalls could negatively affect the company's reputation and financial results. Investors should carefully consider these risks before investing in CNVVY.
How does ConvaTec Group Plc navigate regulatory approval processes?
ConvaTec Group Plc navigates regulatory approval processes by adhering to stringent quality standards and compliance requirements in each of its operating regions. The company works closely with regulatory agencies such as the FDA in the United States and the EMA in Europe to ensure its products meet all necessary safety and efficacy standards. ConvaTec maintains a dedicated regulatory affairs team that monitors changes in regulations and guides the company's product development and approval strategies. The company's track record includes successful approvals for a range of medical devices and technologies.
What revenue streams does ConvaTec Group Plc have in healthcare?
ConvaTec Group Plc generates revenue from several key product lines within the healthcare sector. The largest revenue streams come from advanced wound care and ostomy care products, which are sold to hospitals, clinics, and patients worldwide. Continence and critical care products, including urinary catheters and related devices, also contribute significantly to revenue. Additionally, the company generates revenue from the sale of disposable infusion sets for insulin pumps used in diabetes management. Revenue is further diversified by geographic market, with significant sales in North America, Europe, and emerging markets.
What are the key factors to evaluate for CNVVY?
ConvaTec Group Plc (CNVVY) currently holds an AI score of 43/100, indicating low score. Key strength: Strong market position in wound care and ostomy care.. Primary risk to monitor: Potential: Increasing competition from other medical device companies in the wound care and ostomy care markets.. This is not financial advice.
How frequently does CNVVY data refresh on this page?
CNVVY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CNVVY's recent stock price performance?
Recent price movement in ConvaTec Group Plc (CNVVY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong market position in wound care and ostomy care.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending may provide further insights.
- OTC market data may be less reliable than exchange-listed data.